Douglas G. Watson

BioMimetic Therapeutics, Inc. developed and sells protein therapeutics for tissue and organ regeneration. The company was founded by Samuel E. Lynch and David M. Renzi on April 14, 1999 and was headquartered in Franklin, TN.

BASF Catalysts LLC supplies environmental and process catalysts. Its products include emission-control systems for automobiles and segments produce pigments and performance additives, chemical catalysts and sorbents. The company was founded in 1908 and is headquartered in Iselin, NJ.

The Chartered Institute of Management Accountants, also known as aicpa® & cima®, is a global organization with 689,000 members, students, and professionals. The non-profit company is based in London, UK, and has a global presence of subsidiaries in several regions. The British company advocates for the accounting and finance profession, as well as the public interest and business sustainability. Andrew Harding has been the CEO of the company since 2009.

American Liver Foundation engages in facilitating, advocating and promoting education, support, and research for the prevention, treatment, and cure of liver disease. It educates patients, policymakers and the public and provides grants to early-career researchers to help find a cure for all liver diseases. The company was founded in 1976 and is headquartered in New York, NY.

Engelhard Corp. is a surface and materials science company that provides technologies for environmental, process, appearance and performance applications. It enables customers to improve the productivity of their processes with a wide range of technologies available, it serves a broad range of chemical market segments, including petrochemicals, oleochemicals and fine chemicals.

Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY.

Part of Informedix Holdings, Inc., Informedix, Inc. develops portable and patient-based telehealth technology. The company is based in Rockville, MD.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Wright Medical Group, Inc. designs, manufactures and distributes biologic products. It provides surgical solutions for the foot and ankle markets. The company was founded by Frank O. Wright and is headquartered in Memphis, TN.

Accelerated Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in development of pre-existing pharmaceutical products for the treatment of various cancer indications. It offers a platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications under the Picoplatin brand. The company was founded by Michael Fonstein, Ekaterina E. Nikolaevskaya and Dmitry Prudnikov in May 2014 and is headquartered in Westport, CT.

Bionor Immuno AS engages in the research and development of biomedicine. It also owns and manages shares and other securities. The company was founded on July 14, 2000 and is headquartered in Oslo, Norway.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.